Condensed Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 123,365	$ 129,942
Marketable securities	3,308	3,306
Accounts receivable, net of allowance for doubtful accounts of $164 and $120, respectively	68,755us-gaap_AccountsReceivableNetCurrent	70,758us-gaap_AccountsReceivableNetCurrent
Other receivables	7,914us-gaap_OtherReceivables	5,489us-gaap_OtherReceivables
Inventories	9,079us-gaap_InventoryNet	9,200us-gaap_InventoryNet
Prepaid expenses	3,375	3,774
Deferred tax assets	170us-gaap_DeferredTaxAssetsNetCurrent	0us-gaap_DeferredTaxAssetsNetCurrent
Total current assets	215,966us-gaap_AssetsCurrent	222,469us-gaap_AssetsCurrent
Property and equipment, net of accumulated depreciation	1,313us-gaap_PropertyPlantAndEquipmentNet	1,405us-gaap_PropertyPlantAndEquipmentNet
Intangible assets, net of accumulated amortization	214,606	230,100
Goodwill	17,949us-gaap_Goodwill	18,195us-gaap_Goodwill
Other assets	18,808us-gaap_OtherAssetsNoncurrent	17,864us-gaap_OtherAssetsNoncurrent
Total assets	468,642us-gaap_Assets	490,033us-gaap_Assets
Current liabilities:
Accounts payable and other accrued liabilities	82,153	84,994
Accrued payroll and benefits	4,378us-gaap_AccruedEmployeeBenefitsCurrent	8,444us-gaap_AccruedEmployeeBenefitsCurrent
Deferred revenue	17,045us-gaap_DeferredRevenueCurrent	9,959us-gaap_DeferredRevenueCurrent
Drug development liability	1,141sppi_AccruedDrugDevelopmentCosts	1,141sppi_AccruedDrugDevelopmentCosts
Acquisition-related contingent obligations	5,091	4,901
Total current liabilities	109,808us-gaap_LiabilitiesCurrent	109,439us-gaap_LiabilitiesCurrent
Drug development liability, less current portion	13,978	14,644
Deferred revenue, less current portion	416us-gaap_DeferredRevenueNoncurrent	0us-gaap_DeferredRevenueNoncurrent
Acquisition-related contingent obligations, less current portion	2,751	2,441
Deferred tax liability	6,808	6,569
Other long-term liabilities	6,944	6,088
Convertible senior notes	97,568sppi_ConvertibleSeniorNotes	96,298sppi_ConvertibleSeniorNotes
Total liabilities	238,273us-gaap_Liabilities	235,479us-gaap_Liabilities
Commitments and contingencies
Stockholders’ equity:
Preferred stock
Common stock, $0.001 par value; 175,000,000 shares authorized; 66,905,839 and 65,969,699 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively	66us-gaap_CommonStockValue	66us-gaap_CommonStockValue
Additional paid-in capital	541,157us-gaap_AdditionalPaidInCapital	538,553us-gaap_AdditionalPaidInCapital
Accumulated other comprehensive loss	(2,077)	(850)
Accumulated deficit	(308,900)	(283,338)
Total stockholders’ equity	230,369us-gaap_StockholdersEquity	254,554us-gaap_StockholdersEquity
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	468,642	490,033
Series B junior participating preferred stock [Member]
Stockholders’ equity:
Preferred stock	0	0
Series E Convertible Voting Preferred Stock [Member]
Stockholders’ equity:
Preferred stock	$ 123	$ 123

Carrying value as of the balance sheet date of obligations incurred through that date and payable for drug development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

No definition available.